CHLD
CHANGE OF OWNER RECEIVED FROM IB
01/19/2024
Back to search
Official data from USPTO
OSUMERLI
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
17
Latest update
01/19/2024
Trademark type
Word
Nice classes
5
Filing date
05/24/2022
Registration date
02/14/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/14/2023
Last transaction
02/14/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
HSU, FONG
Law office
O20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sandoz AG
Novartis AG
Representatives
Sandoz International GmbH
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune systemthe metabolic systemthe endocrine systemthe musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
17 publications found
GPNX
NOTIFICATION PROCESSED BY IB
04/23/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
04/03/2023
FIMP
FINAL DISPOSITION PROCESSED
04/03/2023
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
03/16/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
02/14/2023
GPNX
NOTIFICATION PROCESSED BY IB
12/13/2022
PUBO
PUBLISHED FOR OPPOSITION
11/29/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
11/23/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
11/23/2022
NPUB
NOTICE OF PUBLICATION
11/09/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/24/2022
DOCK
ASSIGNED TO EXAMINER
10/17/2022
MAFR
APPLICATION FILING RECEIPT MAILED
08/05/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/01/2022
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/29/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/28/2022
Continuous trademark protection
Get notified about every new filing that threatens OSUMERLI or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.